Kissei Pharmaceutical is a pharmaceutical company engaged in the research and development, manufacture and sale of pharmaceutical products. Co.'s major research and development areas are urogenital system, metabolism and endocrinology, as well as immunology and allergy. Co.'s principal products include a treatment for hyperphosphatemia "P-TOL Chewable," dysuria associated with benign prostatic hyperplasia (BPH) "Urief®," a rapid onset and short acting insulin secretagogue "Glufast®" and a therapeutic agent for patients with dry mouth "Salagenan®." In addition, Co., through its subsidiaries, is engaged in the purchase and sale of primary materials, and the development of information systems.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.